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The Sandwich Technique for Hypogastric Endorevas-
cularization Using Off The Shelf Devices: Three-Year
Results
Armando Lobato, Luciana Camacho-Lobato. ICVE, Sao
Paulo, Brazil
Objectives: To analyze early and mid-term outcomes
in patients undergoing the Sandwich Technique, hypogas-
tric artery (HA) endorevascularization (ER), to treat com-
plex aortoiliac aneurysms (AIA), isolated common iliac
artery aneurysm (ICIAA) and abdominal aortic aneurysms
(AAA) associated with bilateral short, non-diseased com-
mon iliac artery (CIA).
Methods: Between October 2008 and November
2011 52 patients undergoing elective endovascular aneu-
rysm repair (EVAR) for AIA, ICIAA, or AAA with short,
non-diseased CIA were treated using the Sandwich Tech-
nique. Patients were followed through office visits and
CTA Demographic, clinical, and anatomical parameters
and outcomes were recorded. Statistical analysis included
descriptive and non parametric statistical tests (Kruskal-
Wallis and Dunns post Test) for aneurysm sac diameter
assessment (Prism 5, Graphpad Software).
Results: The mean age of the cohort was 73.8 years
and 92.3% of patients were male. The mean follow-up was
15  7.4 months . There was no peri-operative mortality.
60 HA ER (eight patients submitted a bilateral HA ER)
were performed during this prospective study. HA ER
technical success was 100%. Two-year primary HA ER
patency was 93.3%. One late type III endoleak have ap-
peared at 6 months and was not associated with aneurysm
sac enlargement. At three-year, the overall mortality rate
was 3.8%, all unrelated with aneurysm sac rupture. The
assessment of the CIA aneurysm sac diameter by CTA
revealed that 38.3% CIAA had a significant decrease (
least 5 mm), 60% remained stable and 1.7% had an increase
of 6mm. Statistical significance (P.05) was reached only
for comparisons between baseline (0 months) and 30
month measurements (P.027).
Conclusions: The Sandwich Technique, developed to
overcome current anatomical and device constraints, has
the promise of expanding the limits of endovascular aneu-
rysm repair (EVAR) in a safe, easy to perform, and cost-
effectivemanner. It is a useful tool in the armamentarium of
the endovascular surgeon.
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Management of the Left Subclavian Artery and Stroke
after TEVR: Lessons from 1000 Cases in the
MOTHER Registry
Benjamin O. Patterson1, Peter J. Holt1, Alan Karthikesal-
ingam1, Ian M. Loftus1, Ron M. Fairman2, Matt M.
Thompson1. 1St Georges’ Vascular Institute, London,
United Kingdom; 2Hospital of the University of Pennsyl-
vania, Philadelphia, PA
Objectives: Endovascular repair of thoracic aortic an-
eurysms and dissections (TEVR) has been associated with
peri-operative stroke rates as high as 15% in some series.
The objective of this study was to determine the incidence
of peri-operative stroke following TEVR and to define
subsets of patients at increased risk.
Methods: The MOTHER registry is an amalgamation
of five sponsored trials and a single institutional case series
with detailed data on 1010 TEVR. In this study, the
peri-operative stroke rate was investigated. Differences be-
tween groups were quantified through logistic regression
and by comparison of proportions.
Results: Of the 1010 cases, 48 (4.8%) of patients had a
stroke within 30 days. Of these 4 (8.3%) were fatal, but 14
(30%) made a recovery without deficit. Multiple regression
analysis demonstrated that female gender (OR1.9; 95%
CI 1.1-3.4; P.042), renal insufficiency (OR2.1; 95% CI
1.1-4; P.036), history of CVA (OR2.4; 95% CI 1.2-
4.8; P.000) and covering the left subclavian artery with-
out revascularisation (OR 3.6; 95% CI 1.9-6.5; P.000)
were independently predictive of peri-operative stroke.
Mode of admission and type of pathology were not of
significant influence.
Conclusions: Coverage of the left subclavian artery
without re-vascularisation would appear to be the single
most important predictior of post-TEVAR stroke. Not only
is this a strong association, but is potentially modifiable by
appropriate re-vascularisation procedures.
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What Is the Fate of Untreated Concomitant Suprarenal
Aortic Aneurysms Following EVAR
Benjamin J. Herdrich, Erin M. Murphy, Grace J. Wang,
Benjamin M. Jackson, Ronald M. Fairman, Edward Y.
Woo. The University of Pennsylvania School of Medicine,
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Objectives: There are many patients treated with
EVAR who have a concomitant aneurysm of the suprarenal
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aorta (sAAA). The natural history of these sAAAs and
whether they affect the results of EVAR are unknown.
Methods: 470 patients in theM2S database were iden-
tified as having an infrarenal abdominal aortic aneurysm
(iAAA) with a concomitant sAAA (diameter 2.9-4.7cm).
Patients with a preoperative CTA and follow-up imaging
12 months (n239) were included in the analysis. Pa-
tients who did not undergo EVAR served as a control (C)
(n81). Patients with EVARwere subdivided into suprare-
nal fixation (SR) (n94) and infrarenal fixation(IR)
(n64). Standard measurements from the M2S images
were extracted, and growth rates were calculated for differ-
ent abdominal aortic segments.
Results: The average follow-up was 32.1  19.8
months. The average initial size and growth rate of the sAAA
was 34.503.31mm and 0.561.35mm/yr for patients un-
dergoing EVAR (SRIR) compared with 36.683.67mm
(P.05) and 0.602.87mm/yr (P.17) for controls. Fol-
lowing EVAR, 1.3% of patients (SR-1/941.1%; IR
1/641.6%) experienced sAAA growth to a diameter
50mmwhichwas not significantly different from the control
group (4/814.9%, P.09) and occurred at a mean of 43.5
months (range 9.8-59.4). Comparing the SR and IR
groups, there was no difference in the preoperative sAAA
diameter (SR 34.663.09mm, IR 34.263.61, P.75).
Postoperative sAAA growth rate (SR 0.561.20mm/yr, IR
0.551.55, P.98), aortic growth rate at the renals (SR
1.001.81mm/yr, IR 0.901.50, P.69), iAAA growth
rate (SR -1.685.79mm/yr, IR -1.385.09, P.73), and
iAAA change in volume (SR -10.5834.65mL/yr, IR
-6.1129.14, P.40) were also not significantly different.
Conclusions: Isolated treatment of iAAA via EVAR
with a concomitant sAAA is acceptable as the endograft
(suprarenal or infrarenal) does not affect growth rates of the
sAAA. Standard EVAR follow-up is all that is required as
only a small minority demonstrate growth.
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Obstruction of the Endurant Endograft Post-EVAR:
Incidence and Treatment Results
Laura van Zeggeren1, Joost A. van Herwaarden2, Hence J.
Verhagen3, Debbie A. Werson1, Herman J. Zandvoort2,
Frederico B. Goncalves3, Frans L. Moll2, Jean-Paul P. de
Vries1. 1Vascular Surgery, St. Antonius Hospital, Nieu-
wegein, Netherlands; 2UniversityMedical Center, Utrecht,
Netherlands; 3Erasmus Medical Center, Rotterdam,
Netherlands
Objectives: The Endurant endograft was specially de-
veloped to broaden the treatment range for EVAR in
patients with complex aortoiliac anatomy. Preliminary re-
ports showed excellent outcome concerning migration and
type IA endoleaks, but occurrence of post-EVAR obstruc-
tion has not been determined in a large patient cohort with
mid-term follow-up (FU).
Methods: Data of all consecutive patients treated with
the Endurant from December 2007 to April 2011 in 3
Dutch tertiary referral hospitals were prospectively gath-
ered. FU consisted of regular office visits, 1 and 12 months
CT-scans, and annual duplex scanning thereafter. Patients
with either a symptomatic stenosis or complete occlusion of
the Endurant endograft were identified.
Results: 428 patients (88.3% male, mean age 73 years
(range 47-89)) were treated. Median FU was 12 months
(range 0-43). 22 obstructions occurred in 21 patients
(4.9%), either of the main body of the graft (n3), a limb
(n18) or unknown (n1). Median time to obstruction
was 6 months (range 0-22), with 27.3% occurring 12
months post-EVAR. Presenting symptoms were acute isch-
emia (40.9%, Rutherford 2A-B) or non acute (59.1%). The
latter were mainly claudicants without rest pain, and diag-
nosed at regular FU. Treatment was surgical (63.6%) or
percutaneous (18.2%), the remainder was left untreated
due to mild clinical complaints. Initial treatment was suc-
cessful in 19 of 22 obstructions (86.4%), but re-obstruction
occurred in 6 (31.6%). In 40.9%of obstructions a graft related
complication (kinking, stenosis or collapse) was found. Mor-
tality due to obstruction of the endograft was 0.7% (3/428) in
all patients, and 14.3% (3/21) in the obstruction group; 2
patients died because of ongoing ischemia, and 1 patient died
intra-operatively due to bleeding.
Conclusions: Endurant endograft obstruction oc-
curred in 4.9% of 428 patients, and continued during FU.
It is an important complication that must be considered in
expanding the indications for EVAR.
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Video Presentation
Removal of Suprarenal Fixing Aortic Stent Graft and
In Situ Aorto-iliac Reconstruction for a Patient with
Aortic Stent Graft Infection after EVAR
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Sungkyunkwan University School of Medicine, Samsung
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